With a new Congress and many new legislators in key leadership positions, your support today will help RheumPAC start the year off strong.
Search results for: health insurance
ACR Advocacy: 2020 Year in Review
As a new year begins, Government Affairs Committee Chair Blair Solow, MD, takes stock of ACR advocacy wins in 2020 and issues to watch in 2021, including workforce issues, continued telemedicine access, prior authorization relief, Medicare reimbursement and drug pricing.
Marcus Snow, MD, FACR, Assumes Chair of the Committee on Rheumatologic Care
Marcus Snow, MD, FACR, had his first exposure to rheumatology in a rotation during his residency at the University of Nebraska Medical Center, Omaha. James O’Dell, MD, Theodore Mikuls, MD, Jay Moore, MD, Lynn Klassen, MD, and other physicians showed how rheumatology could be the perfect mix of a narrow clinical focus with interesting patient…
The Case for Integrated Musculoskeletal Care Teams
Through the development of a multidisciplinary musculoskeletal institute, we have created a model that facilitates coordination of care of complex patients between medical and surgical subspecialists, physical therapists, dieticians and social workers. A case is presented to demonstrate the improved care experience for both patients and providers and to share our learnings more broadly. The…
The 2020 ARP Merit Awards & ACR Distinguished Fellows
During ACR Convergence 2020 in early November, the ACR and ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the winners of the ARP Merit Awards and the ACR’s Distinguished Fellows. In addition, we bring you the first ever…
Medicare’s Most Favored Nation Is My Least Favorite Notion!
In case you missed it, on Nov. 20, the Centers for Medicare & Medicaid Services (CMS), a department within the U.S. Department of Health and Human Services, announced that it will overhaul the payment system for Medicare Part B (i.e., infusion) drugs on Jan. 1, 2021. The plan is called the Most Favored Nation (MFN)…
Racial Disparities Persist in OA & RA Management
From pain management to arthroplasty, African American patients with OA and RA experience worse outcomes than white patients. But the reasons for these health disparities are difficult to parse from socioeconomic and cultural factors.
Staying Positive & Learning from COVID-19: Q&A with Nilanjana Bose, MD, MBA
Pandemic fatigue is affecting rheumatologists and their patients in different ways, says Nilanjana Bose, MD, MBA. But efforts are being made at her clinic to stay positive and ensure quality patient care.
Outpatient Medicine in the Post-COVID-19 Era of Telemedicine
Our hospitals have had their finest hour in the care of acutely ill inpatients during the COVID-19 pandemic, including dealing with allocation decisions fairly and transparently, maximizing good outcomes and remaining cognizant of the enduring ethics of healthcare. The honorable traditions of self-effacing conduct and acceptance of some level of personal risk by healthcare professionals…
UHC Updates Rituximab Policy to Require Use of Biosimilars
As of Oct. 1, UnitedHealthcare (UHC) requires that patients fail to respond to both FDA-approved rituximab biosimilars prior to receiving approval for rituximab. Exception: Rituximab-pvvr (Ruxience) is not FDA approved for rheumatoid arthritis.
- « Previous Page
- 1
- …
- 63
- 64
- 65
- 66
- 67
- …
- 113
- Next Page »